Abraxane
Abraxane is a pharmaceutical drug with 74 clinical trials. Currently 8 active trials ongoing. Historical success rate of 72.7%.
Success Metrics
Based on 40 completed trials
Phase Distribution
Phase Distribution
29
Early Stage
39
Mid Stage
2
Late Stage
Highest Phase Reached
Phase 3Trial Status & Enrollment
67.8%
40 of 59 finished
32.2%
19 ended early
8
trials recruiting
74
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC
Neoadjuvant Study of HIFU With or Without PD-1 Inhibitors Followed by Abraxane Plus Carboplatin in Triple-Negative Breast Cancer.
Phase II Trial of Albumin-Bound Paclitaxel Combined With Nedaplatin (TP) Via Hepatic Arterial Infusion for Advanced Breast Cancer Patients With Liver Metastases After Failure of Standard Therapy
CAR-DC Vaccine and ICIs in Local Advanced/Metastatic Solid Tumors
A Phase I Dual Dose Escalation Study of Radiation and Nab-Paclitaxel in Patients With Unresectable and Borderline Resectable Pancreatic Cancer
Clinical Trials (74)
Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC
Neoadjuvant Study of HIFU With or Without PD-1 Inhibitors Followed by Abraxane Plus Carboplatin in Triple-Negative Breast Cancer.
Phase II Trial of Albumin-Bound Paclitaxel Combined With Nedaplatin (TP) Via Hepatic Arterial Infusion for Advanced Breast Cancer Patients With Liver Metastases After Failure of Standard Therapy
CAR-DC Vaccine and ICIs in Local Advanced/Metastatic Solid Tumors
A Phase I Dual Dose Escalation Study of Radiation and Nab-Paclitaxel in Patients With Unresectable and Borderline Resectable Pancreatic Cancer
Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)
Bioequivalence Study of Paclitaxel Protein-bound Particles for Injectable Suspension (Albumin-bound) in Breast Cancer Patients
A Study of Hydroxychloroquine in Combination With Gemcitabine/Abraxane in Pancreatic Cancer
A Study of Neoadjuvant Paricalcitol to Target the Microenvironment in Resectable Pancreatic Cancer
9-ING-41 Plus Retifanlimab and Gemcitabine/Nab-Paclitaxel in Patients With Advanced Pancreatic Adenocarcinoma
Romidepsin and Abraxane in Treating Patients With Metastatic Inflammatory Breast Cancer
Abequolixron (RGX-104) and Durvalumab in Lung Cancer
Intravesicular Abraxane for Treatment-Refractory Bladder Cancer
Abraxane With Anti-PD1/PDL1 in Patients With Advanced Urothelial Cancer
ORIN1001 in Patients with Advanced Solid Tumors and Relapsed Refractory Metastatic Breast Cancer
Neoadjuvant Chemotherapy With Nab-paclitaxel in Women With HER2-negative High-risk Breast Cancer
Neoadjuvant Therapy in TRIPle Negative Breast Cancer With antiPDL1
A Phase 2 Feasibility Study of Abraxane and Carboplatin in Epithelial Neoplasms of the Uterus
Phase I/II Study of Weekly Abraxane and RAD001 in Women With Locally Adv. or Metastatic Breast Ca
Combination of CAR-DC Vaccine and ICIs in Malignant Tumors
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 74